Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral seliciclib ((R)-roscovitine) in adults with cystic fibrosis and chronic Pseudomonas aeruginosa infection
2015-002911-13Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Aug 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing Seliciclib with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Aug 2015; status: terminated.
02
Drugs
seliciclib
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-002911-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002911-13.